Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Nuformix Plc is a pharmaceutical company that focuses on the development of cocrystal technology for novel outcomes in drug efficacy and delivery. The company's primary function is to utilize its expertise in pharmaceutical cocrystal intellectual property to improve drug formulation, enhancing bioavailability and therapeutic outcomes. Nuformix targets a wide array of medical and health sectors, with particular emphasis on treating cancer and fibrotic diseases. By developing compositions that enhance existing drug compounds, the company contributes significantly to the pharmaceutical supply chain, creating solutions that can lead to more effective drug therapies. Its strategic role within the financial market highlights the importance of innovation in the biotech sector, aimed at addressing unmet clinical needs and improving patient care. As Nuformix continues to leverage its proprietary technology, it remains a pivotal player in advancing drug development processes and therapeutic innovations.
£0.00
+£0.00 (+0.00%)
EOD Jul 3, 2026
ROIC dropped from -55.90% to -70.98%, capital efficiency is deteriorating. Negative free cash flow of -£615K. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£653K
▲ +82.1% YoY
Op. Margin
—
ROIC
-70.98%
▼ -15.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£615K
▼ -85.2% YoY
Op. Cash Flow (TTM)
-£615K
▼ -85.2% YoY
Net Debt
-£98K
Net Cash Position
Cash & Equiv.
£98K
Continue Research
Nuformix (NFX.XLON)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Nuformix scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Nuformix scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -71.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh NFX.XLON's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.